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ZD1839 (‘Iressa’), an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is currently being
investigated in clinical trials as a treatment for cancer. ‘Iressa’ is a trademark of the AstraZeneca group of companies. We have
previously demonstrated a synergistic interaction between ZD1839 and cisplatin/5-fluorouracil (5FU) in CAL33, a human head and
neck cancer cell line that markedly expresses EGFR. This study examined the effects of this drug combination on the cell cycle, cell
cycle regulators, apoptosis-related factors, EGFR-related signalling and DNA repair in CAL33 cells. The cells were incubated with
ZD1839 alone for 48h, then cisplatin and 5FU were added. Exposure to the drug combination continued for a further 48h. ZD1839
alone induced accumulation of cells in the G0/G1 phase of the cell cycle at 24h accompanied by a concomitant increase in p21, p27
and Bax, a significant decrease in Bcl2 and a decrease in Akt phosphorylation. A decrease in DNA-PK was observed at 48h. ZD1839
alone had no effect on caspase-3 activity, but addition of ZD1839 to cisplatin-5FU led to a significant increase in caspase-3 activity at
96h. Thus, ZD1839 affects key cellular pathways controlling cell proliferation, apoptosis and DNA repair. These data provide a
rationale to support clinical trials combining ZD1839 and cisplatin–5FU and other protocols that combine EGFR-targeting agents
with chemotherapy or radiotherapy.
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ZD1839 (‘Iressa’) is an orally active, selective epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) that blocks
signal transduction pathways implicated in the proliferation and
survival of cancer cells and other host-dependent processes
promoting cancer growth. ‘Iressa’ is a trademark of the
AstraZeneca group of companies. It exhibits a broad spectrum of
antitumour activity against many human solid tumour xenografts
of various origins including breast, pancreas, lung, colorectal and
head and neck (Ciardiello et al, 2000). ZD1839 has shown
promising clinical effectiveness against a range of solid tumours,
most importantly in non-small-cell lung cancer (Fukuoka et al,
2002; Natale et al, 2002). There are numerous experimental data
both in vitro and in vivo showing that EGFR targeting is able to
augment the antitumour activity of several anticancer agents
including doxorubicin, cisplatin, 5-fluorouracil (5FU), gemcita-
bine, paclitaxel and topotecan (Baselga et al, 1993; Fan et al, 1993;
Ciardiello et al, 1999; Bruns et al, 2000; Inoue et al, 2000;
Overholser et al, 2000). Similar enhancement of activity has also
been observed in studies combining EGFR-targeting agents,
particularly the monoclonal antibody IMC C225 (cetuximab), with
ionizing radiation (Huang et al, 1999; Saleh et al, 1999; Bianco et al,
2000; Bonner et al, 2000; Milas et al, 2000). Other investigators
(Williams et al, 2002) and this laboratory (Magne ´ et al, 2002a)
recently showed supra-additive effects between irradiation and
ZD1839, confirming the radiosensitisation conferred by an EGFR-
targeting agent. We also reported a synergistic interaction between
ZD1839 and the cisplatin–5FU combination (Magne ´ et al, 2002a).
This synergistic cytotoxicity observed in vitro in the head and neck
human cancer cell line CAL33 was strictly dependent on the order
of combination, with optimum effects observed when ZD1839 was
applied before and during cisplatin–5FU treatment. The present
study was undertaken to elucidate the cellular mechanisms
underlying the synergistic cytotoxicity of the ZD1839 plus
cisplatin–5FU combination.
Targeting EGFR signalling with specific drugs affects cellular
pathways involved in cell cycle regulation, apoptosis and DNA
repair (Ciardiello et al, 2000; Huang and Harari, 2000; Sirotnak
et al, 2000; Baselga, 2001; Yarden, 2001). The following parameters
were thus investigated in the CAL33 cell line exposed to ZD1839
and cisplatin–5FU: cell proliferation markers (cell cycle, p42/p44,
p-AKT, p21, p27), apoptosis factors (p53, Bax/Bcl2, CD95, caspase
8, caspase 3) and DNA-repair mechanisms (DNA-dependent
protein kinase (DNA-PK), ATM). Changes in glutathione S
transferase p (GSTp) expression were also investigated, as this is
a key factor affecting the chemosensitivity to cisplatin (Cabelgu-
enne et al, 2001).
MATERIALS AND METHODS
Chemicals
ZD1839 was kindly provided by AstraZeneca L, Rveic-Malmaison,
France. Cisplatin and 5FU were provided by the pharmacy of the Received 30 October 2002; revised 15 May 2003; accepted 22 May 2003
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sCentre Antoine Lacassagne (Nice, France). A 50mM working
solution in dimethylsulfoxide (DMSO) was prepared before use.
Dulbecco’s modification of Eagle’s medium (DMEM) and gluta-
mine were purchased from Whittaker (Verviers, Belgium). Fetal
bovine serum (FBS) was obtained from Dutscher (Brumath,
France). Penicillin and streptomycin were from Meyrieux (Lyon,
France). Bovine serum albumin (BSA) and DMSO were purchased
from Sigma (St Quentin Fallavier, France).
Drug administration schedule
The human head and neck cancer cell line CAL33 was used in the
present study as in our previous work (Magne ´ et al, 2002a). CAL33
cells carry a p53 mutation (codon 175: CGC-CAC) and exhibit
high EGFR expression (34000fmolmg
 1 protein). CAL33 has no
intrinsic mitogen-activated protein (MAP) kinase activity or k-ras
mutation (Magne ´ et al, 2002b).
Cells were routinely cultured in DMEM supplemented with 10%
FBS, 2mM glutamine, 50000UL
 l penicillin and 80mM strepto-
mycin, in a humidified incubator (Sanyo, Japan) at 371C with an
atmosphere containing 8% CO2.
Cells were seeded in 175cm
2 tissue culture flasks at 1.86 10
6
cells to obtain exponential growth for the duration of the
experiments. These conditions are comparable to 3000 cells per
well in 96-well microtitration plates, as used in the previously
published study (Magne ´ et al, 2002a).
We investigated two different experimental schedules (Figure 1;
see below), and cellular parameters were analysed at 0, 24, 48, 72
and 96h after T0, the onset of drug application.
Single-drug exposure Cells were exposed, 48h after cell seeding,
to ZD1839 alone at 6mM (IC50) for 96h (condition ZD1839); 48h
after seeding, cells were exposed to medium alone for 48h,
followed by cisplatin and 5FU together at their IC30’s (0.15 and
3.3mM, respectively) for a further 48h (condition cisplatin–5FU;
Figure 1). Cisplatin–5FU was considered to be a single drug for the
purpose of this study.
Drug combination CAL33 cells were exposed, 48h after seeding,
to ZD1839 at 6mM alone for 48h. Cisplatin and 5FU (0.15 and
3.3mM, respectively) were then added, and exposure to the three-
drug combination continued for a further 48h (condition
ZD1839–cisplatin-5FU) (Figure 1). The cytotoxic effects resulting
from this drug combination were analysed as described previously
(Magne ´ et al, 2002a). A mean combination index (according to
Chou and Talalay, 1984) of 0.4 was found, which confirmed the
existence of the previously reported synergistic cytotoxic activity
(Magne ´ et al, 2002a).
All investigations were performed in triplicate during separate
experiments for all cellular parameters.
Cell cycle analysis
Cell cycles were analysed by FACS according to the Vindelov
model. A total of 2 10
6 CAL33 cells in exponential growth were
treated with various concentrations of ZD1839 for 24h and then
washed three times with citrate buffer. The cell pellet was
incubated with trypsin-containing citrate buffer (250ml) for
10min at room temperature and then incubated with 200mlo f
citrate buffer containing a trypsin inhibitor and RNase (10min)
before adding propidium iodide (PI; 200ml at 125mgml
 1).
Samples were analysed on a Becton Dickinson FACScan flow
cytometer using Modfit software, which was also used to determine
the percentage of cells in the different phases of the cell cycle.
Propidium iodide was excited at 488nm, and fluorescence was
analysed at 620nm (Fl-3).
Western blot analyses
The following parameters were analysed by Western blotting: p21,
p27, Bax, Bcl2, p-AKT, p42-p44, DNA-PK and ATM.
Western blots were performed by harvesting total cellular lysates
(4 10
6 cells) in 50ml of lysis buffer Laemmli 1  (Laemmli 4 :
1.6ml Tris-HCl, 1 M, pH 6.8; 400mg sodium dodecyl sulfate (SDS);
2ml glycerol; 145ml b-mercaptoethanol; 12% bromophenol), and
were heated for 15min at 951C. The protein content of cytosolic
preparations was determined by the method of Bradford using the
Bio-Rad reagent with BSA as a standard. Equal amounts of protein
(50mg per lane) were separated by 12.5% SDS–10% polyacrylamide
gel electrophoresis (PAGE) and transferred onto a nitrocellulose
membrane. Prestained molecular weight markers were included in
each gel. Membranes were blocked for 30min in TBS (10mM Tris-
HCl, pH 7.5; 150mM NaCl) with 0.5% Tween-20 and 5% BSA. After
blocking, membranes were incubated for approximately 12h with
the appropriate specific anti-human monoclonal antibody (dilution
of 1:5000) in TBS Tween and 1% BSA: p21 (mouse anti-human
monoclonal anti-p21 antibody, Santa Cruz Biotechnology, Tebu Bio
Le Perray en Yvelyne, France), p27 (mouse anti-human monoclonal
anti-p27 antibody, Santa Cruz Biotechnology), Bax (mouse anti-
human monoclonal anti-Bax antibody, Santa Cruz Biotechnology),
Bcl2 (mouse anti-human monoclonal anti-Bcl2 antibody, Santa
Cruz Biotechnology), phosphorylated form of AKT (p-AKT, goat
anti-human polyclonal anti-p-AKT antibody, Santa Cruz Biotech-
nology), p42–p44 (mouse anti-human monoclonal anti-MAP
kinase activated antibody, diphosphorylated ERK-1&2, anti-
DPERK, clone MAP kinase-YT, Sigma, St Quentin Fallavier,
France), DNA-PK (goat anti-human polyclonal anti-DNA-PK
antibody, Santa Cruz Biotechnology) and ATM (mouse anti-human
monoclonal anti-ATM antibody, Santa Cruz Biotechnology). After
washing the membranes three times with TBS Tween (5min each),
they were incubated with peroxidase-conjugated secondary anti-
bodies purchased from Dako (dilution of 1:1000; Glostrup,
Denmark). A chemoluminescence reaction was performed and
the membranes were exposed to ECL hyperfilm according to the
manufacturer’s instructions (Amersham Pharmacia Biotech, Little
Chalfont, UK). Quantitative analysis of activities was performed by
imaging the autoradiograms and quantitating relative band
densities using scan imaging software (Image Master, Pharmacia,
Amersham Bioscience, Orsay, France).
Medium alone
Cell seeding
−48 h T0 24 h 48 h 72 h 96 h
Time of analysis
ZD1839
ZD1839
Cisplatin − 5-fluorouracil
Cisplatin − 5-fluorouracil
Control
ZD
CPFU
ZDCPFU
Figure 1 Study design. Single-drug exposures: 48h after seeding, cells
were exposed to ZD1839 alone for 96h (condition ZD1839); 48h after
seeding, cells were exposed to medium alone for 48h, followed by
cisplatin–5FU for a further 48h (condition CPFU). Drug combination: 48h
after seeding, CAL33 cells were exposed to ZD1839 (ZD) alone at its IC50
(6mM) for 48h, then exposed to cisplatin and 5FU at their IC30’s in
combination with ZD1839 for a further 48h (condition ZDCPFU).
Mechanism of interaction between ZD1839 and cisplatin-5FU
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sp53 protein assay
p53 protein content (wild type and mutated forms) was analysed in
cytosol (200ml) using a monoclonal two-site single incubation
immunoluminometric assay (LIA-mat, Sangtec, Sweden). A total of
10
7 cells were homogenised in lysis buffer (500ml; 50mM Tris-HCl
pH 6.8, 1% Triton X-100, 2mM phenylmethylsulfonyl fluoride
(PMSF) and 0.02% mercaptoethanol); the samples were then
centrifuged at 105000g for 30min at 41C before 200ml aliquots
were taken. The assay is based on the use of two monoclonal
antibodies against different denaturing-resistant epitopes of the N-
terminal part of the p53 protein. Polystyrene tubes were coated
with PAb 1801 monoclonal anti-p53 antibody and the tracer
consisted of isoluminol-conjugated D01 monoclonal antibody. The
sensitivity limit was 0.002ngmg
 1 protein. The coefficient of
variance for inter-assay reproducibility (pooled cytosol, n¼10)
was 7.66%.
Detection of the CD95 (APO1-fas) receptor
In total, 10
6 cells were trypsinised, washed and exposed to 4ngml
 1
of CH11 anti-Fas MAb for 45min at 41C. After two washing steps,
cells were resuspended in DMEM containing 1:200 (vv
 1) goat
anti-mouse IgM (Immunotech, Marseille, France) and incubated
for an additional 30min at 41C. Cells were then washed twice, and
cell surface expression of CD95 was assessed by FACScan. Analysis
was carried out on a flow cytometer (FACScan, Becton Dickinson)
using Cell Quest Software. Cells exposed to goat anti-mouse IgM
served as negative FITC control. Fas expression was defined as the
fluorescence ratio of CH11 Fas MAb:isotype-matched negative
control MAb. Relative Fas expression in untreated cells was
considered to be 100%.
Mitochondrial energisation
Evaluation of mitochondrial membrane permeability was deter-
mined as the retention of the fluorescence dye
3,30dihexyloxacarbocyanine iodide (DiOC6(3); Sigma). At various
intervals, 2 10
6 cells were washed with PBS, trypsinised and then
placed in DMEM medium. The mitochondrial transmembrane
potential (DCm) was measured with the cationic lipophilic
fluorochrome DiOC6(3). Cells were incubated at 371C for 15min
in the presence of 40nM DiOC6(3), then placed on ice before the
addition of PI (10mgml
 l). The fluorochrome incorporation was
immediately analysed using a Becton Dickinson FACScan flow
cytometer at 488nm (excitation wavelength). Propidium iodide
was used in all samples to exclude dead cells from the analysis.
DiOC6(3) fluorescence was recorded in Fl-1 and PI was recorded in
Fl-3. The percentage of apoptotic cells was calculated from an Fl-1/
Fl-3 scattergram.
Activity of caspases 3 and 8
Caspase activity was measured fluorometrically in cell lysates, as
recommended by the manufacturer (Enzyme Systems Products,
Livermore, CA, USA), using an artificial substrate (AFC-138) that
fluoresces when cleaved (excitation at 400nm, emission at
505nm).
In total, 4 10
6 cells were stimulated as indicated and then
incubated for 30min at 41C in lysis buffer (50mM HEPES pH 7.5,
150mM NaCl, 20mM EDTA, 0.2% Triton X-100, 1mM PMSF,
10mgml
 1 aprotinin). Lysates were cleared at 10000g for 15min at
41C. Protein (100mg) was incubated in a 96-well plate with 0.2mM
of Ac-DEVD-pNA specific for caspase 3 or caspase 8. Caspase
activity was measured at 410nm in the presence or absence of N-
acetyl-Asp-Glu-Val-Asp-CHO (1mM). Specific caspase activity was
expressed in Ac-pNA cleavage or released absorbance.
GSTp expression
GSTp expression was assayed by reverse transcriptase–polymerase
chain reaction (RT–PCR) on cell pellets (3 10
6 cells) stored at
 801C. Total RNA was isolated using the RNA NOW kit from
BIOGENTEX (OZYME, Montigny-le-Bretonneux, France) based on
a method derived from Chomczynski and Sacchi (1987). RNA
quality was checked by agarose gel electrophoresis. Quantification
was performed by densitometric analysis at 260nm. Total RNA
(1mg) was preincubated for 5min at 651Ci na2 0ml final volume of
50mM Tris-HCl (pH 8.3), 75mM KCl, 3mM MgCl2,1 m M of each
deoxyribonucleotide triphosphate and 2mM of random hexamers
(Roche Diagnostics, Meylan, France). In all, 50U Expand Reverse
Transcriptase (Roche Diagnostics, Meylan, France) and 20U
human placenta ribonuclease inhibitor (Amersham Pharmacia
Biotech, les Ulis, France) were then added and the mixture was
incubated for 30min at 421C followed by 5min at 941C. The
oligonucleotides used for GSTp amplification were GSTp sense
strand: TAC ACC GTG GTC TAT TTC CC (nucleotides 27–46) and
GSTp antisense strand: CTG TTT CCC GTT GCC ATT GAT
(nucleotides 627–647), which yield a 620bp product. Those used
for amplification of the reference gene (GAPDH) were GAPDH
sense strand: GGA AGG TGA AGG TCG GAG TC (nucleotides 38–
57) and GAPDH antisense strand: CAC AAG CTT CCC GTT CTC
AG (nucleotides 218–237), which yield a 200bp product. A
LightCycler DNA Master SYBR Green I kit (Roche Molecular
Biochemicals, Meylar, France) was used to perform GSTp RT–PCR
on the LightCycler apparatus. The kit contains MgCl2 25mM,
LightCycler DNA Master SYBR Green I 10  including deoxynu-
cleotide triphosphate mix, MgCl2 10mM, SYBR Green I dye and
Hot Start Taq DNA polymerase. cDNA (2ml), previously obtained,
was amplified in duplicate (one incubation for GSTp, one
incubation for GAPDH, the control gene) in a 20ml reaction
capillary containing 2ml of LightCycler DNA Master SYBR Green I
10 , 1.6mlo f2 5m M MgCl2 and 4ml of one pair of primers 2.5mM.
In each experiment, a cDNA preparation of the RNA extracted
from another CAL33 culture was introduced as the calibrator.
Simultaneously, a blank was prepared as the negative control by
incubating H2O PCR grade instead of cDNA. The PCR protocol
programmed on the LightCycler software consisted of three steps.
The first step was denaturation of cDNA and activation of the
enzyme for 8min at 951C. In the second step, DNA was amplified
for 45 cycles of 15s at 951C, 13s at 611C and 26s at 721C. In the
third step, the temperature was raised gradually (0.11Cs
 1) from
the annealing temperature to 951C to obtain melting curves and
fusion temperatures of the amplicons synthesised. Results,
calculated using RelQuant software, were expressed as the ratio
of concentration of GSTp to GAPDH for a given sample,
normalised by the same ratio for the calibrator.
Statistical analysis
Differences between the mean values were evaluated using either
one-way ANOVA with Tukey’s test or one-way ANOVA on ranks
with Dunnetts’ or Student–Newman–Keuls test, according to data
distribution. P¼0.05 was regarded as statistically significant. All
analyses used SPSS software (Paris, France).
RESULTS AND DISCUSSION
Effects on cell proliferation (Figures 2, 3 and 9)
In the absence of drugs, CAL33 cell numbers increased approxi-
mately five-fold over 96h. Figure 2A shows that ZD1839 markedly
inhibited cell proliferation in a time-dependent manner. At the end
of the longest drug exposure tested (96h), ZD1839 reduced the
final cell number by 60%; cisplatin–5FU had a similar effect. The
combination of ZD1839 and cisplatin–5FU reduced the final cell
Mechanism of interaction between ZD1839 and cisplatin-5FU
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snumber at 96h six-fold compared with untreated cells. This degree
of decrease in cell numbers suggests at least additivity. Previously,
we have reported synergy when combining ZD1839 and cisplatin–
5FU under identical experimental conditions (Magne ´ et al, 2002a).
Flow cytometry analysis showed that the application of ZD1839
led to an accumulation in the percentage of cells in the G0/G1
phase compared with control (25% higher, maximal effect at 24h,
Figure 2B) and this result was not dependent upon exposure time.
Fewer cells exposed to ZD1839 were in the S phase, regardless of
the duration of exposure. The cell cycle effects of ZD1839 and the
cisplatin–5FU combination were quite different: the latter treat-
ment generated a greater proportion of cells gathered in the S
phase. It is interesting to note that the final cell cycle effects when
ZD1839 was combined with cisplatin–5FU were very similar to
those observed after ZD1839 alone. The fact that ZD1839 enhances
the proportion of cells in the G1 phase may favour the effect of 5FU
through incorporation into RNA, as previously pointed out by
Maybaum et al (1980).
Cyclin-dependent kinase (CDK) inhibitors are proteins that
regulate the activities of CDK/cyclin complexes during the cell
cycle. Many of the identified inhibitors, such as p21
WAF1 and
p27
Kip1, act on G1-dependent kinases. ZD1839 exposure led, in
CAL33 cells, to early increased expression of p21
WAF1 and p27
Kip1
with a maximum increase of 1.5- and two-fold, respectively, after
24h (Figure 2C and D). These effects of ZD1839 on p21
WAF1 and
p27
Kip1 agree well with those observed on the cell cycle. The
present data obtained with ZD1839 are in line with previous data
on tumour cells of head and neck origin concerning the
upregulation of p27
Kip1 caused by EGFR targeting with a specific
monoclonal antibody (Huang et al, 1999). The cisplatin–5FU
combination did not modify the cellular levels of these CDK
inhibitors and no modulatory effect was observed in association
with ZD1839.
We next examined the effects of ZD1839 on the final steps of
EGFR signalling, p42/p44 (activated MAP kinase) and AKT (PI3
kinase pathway). Treatment of CAL33 cells with ZD1839 sig-
nificantly reduced the level of phosphorylation of both MAP kinase
and AKT (Figure 3A and B). Importantly, ZD1839 reduced p42/p44
levels by 25% at 72 and 96h, and it is interesting to note that these
inhibitory effects were more marked (approximately a reduction of
two-fold) and occurred earlier on AKT phosphorylation than on
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Figure 2 Impact of ZD1839 (6mM) and cisplatin–5FU (0.15 and 3.3mM, respectively) on cell proliferation and related molecular markers: (A) time-related
impact of drugs on cell proliferation, (B) effect of ZD1839 on cell cycle at 24h, (C) influence of drugs and drug combinations on p21 and (D) influence of
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phosphorylation. (B) ZD1839 (6mM,I C 50 value) diminished AKT
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sp42/p44. The impact of cisplatin–5FU on p42/p44 was comparable
to that observed in cells treated with ZD1839 alone. In contrast,
treatment with cisplatin–5FU did not induce marked changes in
AKT phosphorylation. For both p-MAP kinase and p-AKT, the
combination of cisplatin–5FU with ZD1839 did not generally lead
to greater effects than cisplatin–5FU alone or ZD1839 alone. These
observations support the recent data reported by other investiga-
tors showing that EGFR antagonists deplete the activation of both
PI3 kinase and MAP kinase in human head and neck cancer cell
lines (Bancroft et al, 2002) and human breast cancer cell lines
(Normanno et al, 2002).
Effects on apoptosis (Figures 4–7 and 9)
As concerns the exploration of parameters linked to apoptosis,
there are two different well-identified pathways. First, the
mitochondrial route, which reacts to various stimuli of cell
aggression (internal or external). This apoptotic pathway is
initiated by a change in mitochondrial permeability, which is
regulated by Bcl2-related proteins, and more particularly by the
Bax/Bcl2 ratio, which is under the control of p53; the mitochon-
drial efflux in cytochrome C leads to the immediate activation of
caspase 9 followed by the activation of the effector caspase 3. This
later caspase catalyses the degradation of various proteins linked
to vital cellular processes. Since a Bax/Bcl2-mediated pathway has
been implicated in the response to effective drug treatment, we
examined the changes in these pro- and antiapoptotic proteins in
the presence of each agent. As shown in Figure 4A and B, ZD1839
alone caused a downregulation of Bcl2 and an upregulation of Bax;
both changes were already evident 24h after treatment. Cisplatin–
5FU had similar effects. As a corollary, ZD1839 alone caused an
early and marked increase in the Bax/Bcl2 ratio maintained during
all drug exposure and without modulatory effect caused by
cisplatin–5FU (Figure 4C). This biochemical event likely reflects
the capacity of EGFR targeting to upregulate the intrinsic apoptotic
capacity of treated cells, as has been demonstrated by others
(Ciardiello et al, 2002).
It is well established that, at an early stage, apoptotic stimuli
alter DCm. We used the ampholytic cationic fluorochrome
DiOC6(3) to monitor the changes in DCm induced by ZD1839.
Results are shown in Figure 5. Cells treated for different lengths of
time exhibited differences in fluorescence intensity. After 48h of
ZD1839 exposure, the maximum decrease in cellular uptake of the
fluorochrome measured with the DiOC6 probe reflects the collapse
of DCm, which is a signature for the opening of the mitochondrial
megachannels, also called the permeability transition pores, in
favour of involvement of the mitochondrial apoptotic pathway. In
contrast, we observed an increase in DiOC6(3) fluorescence after 72
and 96h of drug exposure, whatever the applied drug, although the
Bax/Bcl2 ratio remained high.
Apart from the mitochondrial route, the cell death signal can be
mediated through a receptor–ligand interaction via a membrane-
linked death receptor family represented by tumour necrosis factor
(TNF) and Fas. Fas (APO-1/CD95) is a member of the TNF
receptor superfamily and can induce apoptosis when activated by
its ligand FasL or by agonistic antibodies. The signalling cascade is
initiated through the formation of a membrane death-inducing
signalling complex that involves the recruitment of Fas-associated
death domain protein and caspase 8. Neighbouring caspase
8molecules within this newly formed multiprotein complex allow
proteolytic autoactivation and the subsequent cleavage of down-
stream effector caspases (caspases 3, 6 and 7), leading to cell death.
The impact of ZD1839 with or without cisplatin–5FU on Fas
receptor expression and on caspase 8 activity was examined.
Neither ZD1839 nor cisplatin–5FU had an impact on Fas receptor
expression whatever the time of exposure (data not shown). This
result is surprising because it has recently been shown that 5FU
induces apoptosis, possibly via the Fas pathway (Backus et al,
2001). It seems, however, that Fas-mediated apoptosis stimulated
by 5FU is dependent upon wild-type p53 status (Petak et al, 2000),
a condition that is not fulfilled by the CAL33 cell line used in the
present study. The lack of impact of ZD1839 on the death receptor
pathway was confirmed by the absence of caspase 8 activity,
whatever the applied drug and time of exposure (data not shown).
Results concerning caspase 3 were more informative. Interest-
ingly, ZD1839 alone had no effect on caspase 3 activity, but the
addition of ZD1839 to cisplatin–5FU led to a marked increase in
*
*
*
*
B
A
C
24 48 72 96
Time after ZD1839 onset (h)
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
2.5
5.0
7.5
10.0
24 48 72 96
24 48 72 96
Time after ZD1839 onset (h)
Time after ZD1839 onset (h)
Control
ZD1839
CPFU
ZDCPFU
B
a
x
 
e
x
p
r
e
s
s
i
o
n
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
B
c
l
2
 
e
x
p
r
e
s
s
i
o
n
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
B
a
x
/
b
c
l
2
 
r
a
t
i
o
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
Figure 4 ZD1839 and cisplatin–5FU alone caused an upregulation of
Bax (A) and a downregulation of Bcl2 (B), and no additive effect was
observed when ZD1839 was combined with cisplatin–5FU. Results
confirmed by the Bax/Bcl2 ratio (C). *Po0.05 vs control, bars indicate
standard deviation from the mean of three separate experiments.
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Figure 5 Impact of the applied drugs on mitochondrial energisation.
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scaspase 3 activity at 96h (Figure 6). Recently, caspase 3 activation
has been shown to play an important role in cisplatin-induced
apoptosis and to precede the morphological changes typical to
apoptosis (Kolfschoten et al, 2002). We feel the supra-additive
increase in caspase 3 activity in the presence of ZD1839 and
cisplatin–5FU is a molecular illustration of the synergistic
interaction observed with this drug combination (Magne ´ et al,
2002a). It is also interesting that ZD1839 alone had a minor effect
on caspase 3 activity (only visible at 96h) despite the fact that this
drug was able to markedly upregulate the Bax/Bcl2 ratio. This later
observation may be considered as a biochemical explanation of the
radio- and chemo-sensitisation provided by EGFR-targeting drugs
like ZD1839, which would be sustained by an underlying
mechanism of enhancement of the intrinsic cellular apoptotic
capacity.
It was striking to note that ZD1839 alone was able to markedly
diminish p53 expression at 24–72h with a maximum 2.5-fold
decrease at 48h; the inhibitory effect was smaller at 96h (Figure 7).
Moreover, cisplatin–5FU alone or in association with ZD1839 had
strictly no effect on p53 expression compared with controls at 72–
96h. Since changes in Bcl2 and Bax are in a great part under the
control of p53 (Johnstone et al, 2002), one would expect the
increase in Bax and the concomitant decrease in Bcl2 under
ZD1839 to be accompanied by an upregulation of p53 levels in the
presence of ZD1839. The same deduction holds true for the
changes in p21 and those expected for p53. We have no clear
explanation for these apparent contradictions; the present cell line
was p53 mutated; this fact must be taken into consideration and it
is plausible that this p53 status may influence the regulation of this
protein under ZD1839. Thus, the fact that EGFR targeting modifies
p53 cellular status merits further investigation.
Effects on DNA repair and detoxification mechanisms
(Figures 8 and 9)
DNA damage activates several protein kinases, of which the
prototypes are ATM, mutated in the human autosomal recessive
disorder ataxia telangiectasia, and DNA-PK. A target of ATM is the
tumour suppressor p53, maintained at low levels through
interaction with the MDM2 protein that signals p53 degradation.
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Figure 6 Impact of drugs and drug combination on caspase 3 activity.
ZD1839 alone had no effect on caspase 3 activity, but the combination of
ZD1839 with cisplatin–5FU led to a supra-additive increase in caspase 3
activity at 96h. *Po0.05 vs CFPU combination, bars indicate standard
deviation from the mean of three separate experiments.
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Figure 7 Impact of drugs and drug combination on p53. *Po0.05 vs
control, bars indicate standard deviation from the mean of three separate
experiments.
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Figure 8 Impact of drugs and drug combination on DNA-PK. *Po0.05
vs control, bars indicate standard deviation from the mean of three
separate experiments.
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Figure 9 Representative Western blots related to Figures 2–4 and 8.
For details on these analyses, see Materials and Methods section.
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sMDM2 is itself a target for DNA-PK. ZD1839 alone reduced DNA-
PK expression by 25% compared with control. The application of
cisplatin–5FU slightly increased DNA-PK expression (Figure 8).
The combination of ZD1839 and cisplatin–5FU significantly
reduced DNA-PK expression at 72 and 96h. There was no impact
on the DNA-repair protein ATM whatever the exposure time or the
drug applied. The impact of ZD1839 on DNA-PK expression may
be one explanatory phenomenon for the synergistic interaction
between ZD1839 and cisplatin–5FU, because DNA repair is one of
the biochemical modulators of cisplatin sensitivity (Perez, 1998).
Furthermore, DNA-PK is involved in the repair of radiation-
induced DNA damage, suggesting a role for ZD1839 in radio-
sensitisation.
Glutathione, GSTp and glutathione conjugate export pump have
been shown to participate collectively in the detoxification of many
anticancer drugs, including cisplatin (Perez, 1998). ZD1839
upregulated GSTp expression after 24–72h of exposure, with a
maximum two-fold increase after 48h. Similarly, cisplatin–5FU
upregulated GSTp at 96h. The combination of ZD1839 and
cisplatin–5FU did not lead to additional effects on GSTp.I n
contrast to the impact of ZD1839 on DNA-PK, this latter
observation is not consistent with a synergistic interaction
resulting from combining ZD1839 with cisplatin–5FU.
In summary, the present experimental study brings together
numerous biochemical arguments that may sustain not only
chemo-sensitisation but also radio-sensitisation (impact on DNA-
PK) conferred by EGFR targeting. ZD1839 was thus able to
impact on key cellular pathways controlling cell proliferation,
apoptosis and DNA repair. Although the observations were
obtained on a single human cancer cell line, the present
data may serve as a rational basis to support clinical trials
combining ZD1839 and cisplatin–5FU and also other protocols
that combine EGFR targeting with chemotherapeutic drugs or
radiotherapy.
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